TOP TEN perturbations for 1553420_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1553420_at
Selected probe(set): 235147_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1553420_at (235147_at) across 6537 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Relative Expression (log2-ratio):-5.163404Number of Samples:6 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):-4.1608367Number of Samples:6 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):3.721548Number of Samples:22 / 4
Experimental | expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS). | |
Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):3.6676254Number of Samples:4 / 2
Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Relative Expression (log2-ratio):-3.5928698Number of Samples:2 / 2
Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
Control | CNS cancer study 1 (PDX; ependymoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted). |
ulcerative colitis study 17 (5-ASA / AZA) / ulcerative colitis study 17 (5-ASA)
Relative Expression (log2-ratio):-3.5153875Number of Samples:2 / 2
Experimental | ulcerative colitis study 17 (5-ASA / AZA) |
Mucosa tissue from sigmoid colon derived from patients with ulcerative colitis treated with mesalazine (5-ASA) in combination with azathioprine (AZA). Biopsies were collected from non-inflamed tissue and histological examination showed no cellular infiltration or tissue damage. Ulcerative colitis (UC) was diagnosed based on endoscopic, histological and radiological criteria and based on a permanent, colon exclusive, inflammation state. All patients showed mild to active disease state (colitis activity index from 2 to 7) and received no antibiotic therapy at least in the last 6 months before investigation. All patients investigated are UC discordant twins. | |
Control | ulcerative colitis study 17 (5-ASA) |
Mucosa tissue from sigmoid colon derived from patients with ulcerative colitis treated with mesalazine (5-ASA). Biopsies were collected from non-inflamed tissue and histological examination showed no cellular infiltration or tissue damage. Ulcerative colitis (UC) was diagnosed based on endoscopic, histological and radiological criteria and based on a permanent, colon exclusive, inflammation state. All patients showed mild to active disease state (colitis activity index from 2 to 7) and received no antibiotic therapy at least in the last 6 months before investigation. All patients investigated are UC discordant twins. |
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):3.4682894Number of Samples:4 / 4
Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; adenosquamous carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted). |
osteoarthritis study 3 / normal chondrocyte sample
Relative Expression (log2-ratio):3.4187183Number of Samples:2 / 2
Experimental | osteoarthritis study 3 |
Osteocytes/-blasts in P2 from human bone chips from patients with osteoarthritis. | |
Control | normal chondrocyte sample |
Healthy chondrocytes. |
glioma study 17 (oligodendroglioma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):3.3031492Number of Samples:3 / 3
Experimental | glioma study 17 (oligodendroglioma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from low grade oligodendroglioma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 39 ± 9 years old. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):3.2501469Number of Samples:3 / 6
Experimental | stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) |
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
Control | stem cell differentiation study 47 (0d) |
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |